Connect Doses Asthma Patients in Global Trial of Interleukin Antibody

Connect Biopharma, a Taicang-San Diego company, has dosed the first patient in a global Phase II trial testing CBP-201 in adults with moderate-to-severe persistent asthma who have Type 2 inflammation. CBP-201 is an interleukin-4 receptor alpha (IL-4Rα) antibody that has already started trials for atopic dermatitis and is also in development to treat chronic rhinosinusitis with nasal polyps. The asthma trial will administer two doses of CBP-201 to 300 patients in the US , China , EU and other sites. More details.... Stock Symbol: (NSDQ: CNTB) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.